drugset / Trial / NCT05981157
Anrotinib and Tirelizumab in First-line Treatment of RM-NPC
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective phase II clinical trial to evaluate the efficacy and safety of Anrotinib and Tirelizumab as a first-line treatment in patients with advanced recurrent or metastatic nasopharyngeal carcinoma.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2025-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anrotinib | Unknown | 10 mg | — |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | — |